Bruker Corporation (BKD.F)
| Previous Close | 75.40 |
| Open | 73.38 |
| Bid | 70.06 x 60000 |
| Ask | 71.08 x 60000 |
| Day's Range | 73.38 - 73.38 |
| 52 Week Range | 51.50 - 86.50 |
| Volume | |
| Avg. Volume | 54 |
| Market Cap | 10.665B |
| Beta (5Y Monthly) | 1.18 |
| PE Ratio (TTM) | 27.08 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.18 (0.24%) |
| Ex-Dividend Date | Feb 29, 2024 |
| 1y Target Est | N/A |
- Business Wire
Bruker Reports First Quarter 2024 Financial Results
BILLERICA, Mass., May 02, 2024--Bruker Corporation (Nasdaq: BRKR) today announced financial results for its first quarter ended March 31, 2024.
- Business Wire
Bruker Completes Acquisition of Molecular Diagnostics Innovator ELITech
TORINO, Italy, May 02, 2024--Bruker Corporation (Nasdaq: BRKR) is pleased to announce the closing of its acquisition of ELITechGroup ("ELITech") for €870 million in cash, excluding the carved out ELITech clinical chemistry business. ELITech is a differentiated, fast growing and profitable provider of systems and assays for molecular diagnostics (MDx), biomedical systems/specialty IVD, and microbiology, with FY 2023 revenue of approximately EUR 150 million, and more than 80% consumables revenue.
- Business Wire
Bruker Further Enhances Clinical Microbiology & Infection Diagnostics Portfolio at ESCMID Global 2024 Conference
BARCELONA, Spain, April 26, 2024--At the ESCMID Global 2024 conference, Bruker is enhancing its innovative diagnostic solutions in microbial identification, antimicrobial susceptibility testing (AST), early sepsis diagnostics, and other infectious disease assays. Simplifying microbiology and infectious disease diagnostics and workflows in the clinical laboratory is a key goal for Bruker in support of earlier and improved patient treatment decisions.
